An interventional study of Orem's Self-Care Nursing Program in Thalassemia Majors (Beta-Thalassemia Major), sponsored by University of Baghdad. Not yet recruiting at 1 site in Iraq. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by University of Baghdad · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate the effect of a nursing intervention based on Orem's self-care theory on treatment burden and self-management among adolescents diagnosed with thalassemia. Adolescents with thalassemia face significant physical and psychosocial challenges that affect their daily routines and treatment adherence. The intervention consists of educational and supportive sessions designed to enhance self-care agency and reduce treatment burden. Participants will be evaluated before and after the implementation of the nursing program to measure changes in treatment burden and self-management behaviors.
295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.
This study's planned enrollment of 150 is above the median of 40 across 209 interventional studies indexed under beta-Thalassemia.
Browse beta-Thalassemia studies →University of Baghdad is the lead sponsor of 172 studies on the registry; 70 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Orem's Self-Care Nursing Program
A structured educational and supportive nursing program based on Orem's self-care theory, designed to enhance self-care agency, improve disease self-management, and reduce treatment burden among adolescents with thalassemia
Self-management
Mean Score of Self-Management Measured by the Self-management and transition to adulthood with Rx (STARx). Self-management behaviors will be assessed using a validated Self-Management Questionnaire. The total score ranges from \[0\] to \[90\], where higher scores indicate better self-management practices. Baseline (pre-intervention) and 8 weeks post-intervention
Time frame: 8 weeks
Treatment Burden
Treatment burden will be evaluated using the validated The Medication-Related Burden Quality of Life (MRB-QoL) . The total score ranges from \[31\] to \[155\], where higher scores indicate a greater perceived burden of treatment Baseline (pre-intervention) and 8 weeks post-intervention
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Feb 2027, 2 months later.
Of 29 interventional studies with no phase under beta-Thalassemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 69. This study's planned 2 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.